NuoSiLande Shanghai Branch Grand Opening: Full-Scale Commercialization of Gene Therapy Drug NL003 Underway

Xu Songshan, Chairman of the company, delivered a speech. He first reviewed the 20-year development history of Northland. Northland was established in Haidian District, Beijing in 2004. Currently, it has formed a main business that integrates the research and development, production, and operation of biopharmaceuticals and ophthalmic drugs. It is a high-tech enterprise driven by technological innovation and recognized as a "specialized, refined, distinctive, and innovative" company. In 2021, it was among the first batch of companies to be listed on the Beijing Stock Exchange.CompanyFocusing on the development of gene therapy drugs, three biotech new drugs have entered the clinical research stage; the rapid growth in the operation of ophthalmic drugs has become a solid foundation for Northland's sustainable development.The company's core project, "Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection" (code name NL003), has now completed Phase III clinical trials, with indications for severe lower limb ischemic disease.According to incomplete statistics, there are approximately 4.5 million patients in China, and currently, there are no clinical treatments available. The market launch of this drug will change the current situation of having no effective treatment in clinical practice, providing a new, effective, and safe treatment option for clinicians. This project is currently in the new drug marketing registration review stage.Expected to be approved for marketing next year, it will become China's first plasmid-based gene therapy drug.。To deploy the commercialization of NL003, the company has established a branch in Shanghai, which will serve as the base for sales operations. Collaborating with a wide range of agents, the company aims to build a nationwide sales channel in China and steadily develop and penetrate the pharmaceutical market.

Lan Tian, Deputy Director of the Tianmu West Road Subdistrict Office in Jing'an District, delivered a speech on behalf of the local leaders. He welcomed Northland to Shanghai, comprehensively introduced the industrial environment, investment promotion, and industrial policies of Jing'an District, and expressed that they would provide thoughtful and meticulous services to the company. He congratulated Northland on the smooth launch of its commercial operations in Shanghai.

The guests present at the ceremony performed the ribbon-cutting for the opening of the Shanghai branch. Xu Songshan, Chairman of the company, and Zhao Lei, General Manager of the Shanghai branch, unveiled the branch office plaque, officially announcing the operation of Northland's pharmaceutical sales center.

The establishment of Northland's Shanghai branch is an important part of the company’s strategic plan and a new starting point for commercialization. It marks a significant milestone in the company’s transition from a Biotech to a Biopharm, integrating research, production, and sales. We look forward to the early approval and market launch of the gene therapy drug NL003. The company will strive to develop this new drug into a "blockbuster" medication, creating strong economic and social benefits.

Tweet link:First in China! Northland's Gene Therapy New Drug NL003 Phase III Clinical Trial Unblinded）